A real-world study finds cardiovascular and survival benefits from dual therapy in patients with type 2 diabetes.

Medicare does cover GLP-1 drugs when prescribed for conditions like diabetes and heart disease, but legislation from 2003 prohibits Medicare from covering drugs for weight loss. There is a ...

SAN DIEGO — GLP-1 agonists may lead to increased nausea and vomiting in the early postoperative period after total hip arthroplasty, according to results presented here. “Orthopedic surgeons ...

Look treated him with a newer GLP-1 RA, and the patient experienced a dramatic response where he lost significant weight in a short period of time, she said. When Look analyzed his body ...

The therapeutic potential of targeting glucagon-like peptide-1 (GLP-1) has become increasingly evident over the past 20 years, both as notable diabetes and weight loss drugs, such as exenatide, ...

Although grateful for the recognition, she noted that this has been a huge team effort. “When you see a success story like GLP-1, there are multiple inventors.” In the 1980s, Habener was working at ...

OneSource Specialty Pharma Limited, an Indian contract development and manufacturing organisation (CDMO), is gearing up to capture a 15-20% share in the generic GLP-1 market by FY27-28 ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation ...

The Trump administration has decided not to back a Biden administration plan that would have allowed Medicare to pay for obesity drugs, according to a report from Bloomberg. Shares of both Eli ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making versions of one of its GLP-1 agonist drugs. The latest attempt focuses ...